Mckesson CORP

McKesson Corporation's annual shareholder meeting saw the re-election of all director nominees and the ratification of Deloitte & Touche LLP as independent auditors, with advisory approval for executive compensation.

McKesson Corporation announces the retirement of its Chief Strategy and Business Development Officer and appoints a successor, alongside disclosures of maturing debt.

McKesson Corporation announces a $2.25 billion senior secured term B loan facility due 2032, amending its existing credit agreement.

McKesson Corporation announced robust fourth quarter and full fiscal year 2026 results, exceeding long-term growth targets, and provided positive guidance for fiscal year 2027.

McKesson Corporation has entered into a new $5 billion revolving credit facility, replacing its existing credit lines and extending its maturity to April 2031.

McKesson Medical-Surgical Top Holdings Inc. entered into a $2.0 billion senior secured credit agreement to support working capital and general corporate purposes.

McKesson Corporation announced significant revenue and profit increases for the third quarter and first nine months of fiscal 2026, driven by strategic acquisitions and market growth.

McKesson Corporation announced significantly increased revenues, net income, and diluted EPS for the second quarter and first half of fiscal 2026, driven by market growth and strategic acquisitions.

McKesson Corporation reported a 14% decline in net income for the first fiscal quarter of 2026, primarily due to a significant bad debt provision related to Rite Aid's second bankruptcy filing, despite robust revenue growth.

McKesson's Q3 results show strong revenue growth driven by the U.S. Pharmaceutical segment, but earnings are impacted by divestiture-related charges and restructuring initiatives.

McKesson's Q2 results show a revenue increase but a significant drop in net income due to restructuring charges and a divestiture.

McKesson Corporation's first quarter results show a revenue increase but a slight decrease in earnings per share, impacted by opioid litigation charges and strategic restructuring.

McKesson Corporation's 10-K filing details the company's securities, governance, and operational framework, including common stock details, debt obligations, and compliance measures.

McKesson Corporation's 2024 annual report highlights a 12% revenue increase, strategic investments in technology and data analytics, and challenges from opioid litigation and customer bankruptcy.

James H. Hinton, a Director of Mckesson Corp, received 277 shares of common stock on July 22, 2026.

Lynne M Doughtie, a Director of Mckesson Corp, received 277 shares of common stock on July 22, 2026.

Kathleen Wilson-Thompson, a Director of Mckesson Corp, received 277 shares of common stock on July 22, 2026.

Webster Roy Dunbar, a Director of Mckesson Corp, received 277 shares of common stock on July 22, 2026.

Dominic J Caruso, a Director of Mckesson Corp, received 277 shares of common stock on July 22, 2026.

Julie L. Gerberding, a Director of Mckesson Corp, received 277 shares of common stock on July 22, 2026.

McKesson Corporation's 2026 proxy statement outlines board leadership transitions, executive compensation structures, and strategic priorities focused on healthcare services and AI integration.

McKesson Corporation reported robust fiscal year 2025 financial results, including significant revenue and earnings growth, alongside strategic advancements in oncology and biopharma services and enhanced corporate governance practices.

McKesson Corporation has filed its definitive proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission, as required by Section 14(a) of the Securities Exchange Act of 1934.

McKesson Corporation's recent DEF 14A filing highlights a 25% stock price increase in fiscal year 2025, driven by disciplined execution of strategic priorities, including portfolio modernization and enhanced oncology and biopharma services, alongside robust corporate governance and a focus on people and culture.

McKesson's proxy statement highlights key governance updates, executive compensation structures, and strategic priorities for the upcoming year, including shareholder engagement and board composition.

McKesson Corporation has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Vanguard Capital Management has reported a beneficial ownership of 7.49% in McKesson Corp's common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in McKesson Corp common stock following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.3% beneficial ownership stake in McKesson Corporation as of March 31, 2025, held for ordinary course of business.